靶向CD19的嵌合抗原受体T细胞免疫疗法治疗弥漫性大B细胞淋巴瘤。回复。 - Suppr

Suppr

超能文献

Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. Reply.

作者信息

Schuster Stephen J

机构信息

University of Pennsylvania, Philadelphia, PA

出版信息

N Engl J Med. 2019 Apr 18;380(16):1586. doi: 10.1056/NEJMc1901464.

DOI:10.1056/NEJMc1901464

PMID:30995384

Abstract

摘要

相似文献

Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. Reply.

N Engl J Med. 2019 Apr 18;380(16):1586. doi: 10.1056/NEJMc1901464.

Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2019 Apr 18;380(16):1585-1586. doi: 10.1056/NEJMc1901464.

Tisagenlecleucel in Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2019 Apr 18;380(16):1585. doi: 10.1056/NEJMc1901464.

The use of CAR T cells in diffuse large B-cell lymphoma and mantle cell lymphoma.

Clin Adv Hematol Oncol. 2017 Apr;15(4):247-249.

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

Mol Ther. 2017 Oct 4;25(10):2245-2253. doi: 10.1016/j.ymthe.2017.07.004. Epub 2017 Jul 13.

Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.

Drugs Today (Barc). 2017 Nov;53(11):597-608. doi: 10.1358/dot.2017.53.11.2725754.

The Promise and Challenges of CAR-T Gene Therapy.

JAMA. 2017 Dec 12;318(22):2167-2169. doi: 10.1001/jama.2017.15605.

[Not Available].

Bull Cancer. 2018 Dec;105 Suppl 2:S214-S217. doi: 10.1016/S0007-4551(19)30052-9.

Tisagenlecleucel (Kymriah) for ALL.

Med Lett Drugs Ther. 2017 Oct 23;59(1532):177-178.

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

N Engl J Med. 2017 Aug 24;377(8):783-784. doi: 10.1056/NEJMc1704610.

引用本文的文献

[F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis.

Eur J Radiol Open. 2025 Jun 5;14:100663. doi: 10.1016/j.ejro.2025.100663. eCollection 2025 Jun.

Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies.

Br J Haematol. 2025 Jun;206(6):1834-1839. doi: 10.1111/bjh.20104. Epub 2025 Apr 23.

Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia.

Discov Oncol. 2025 Feb 14;16(1):181. doi: 10.1007/s12672-025-01860-5.

Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties.

Int J Mol Sci. 2024 Aug 8;25(16):8662. doi: 10.3390/ijms25168662.

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.

J Hematol Oncol. 2022 Nov 8;15(1):164. doi: 10.1186/s13045-022-01382-5.

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.

Front Immunol. 2022 Aug 23;13:879608. doi: 10.3389/fimmu.2022.879608. eCollection 2022.

Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.

Leuk Lymphoma. 2022 Oct;63(10):2469-2473. doi: 10.1080/10428194.2022.2076853. Epub 2022 Jun 9.

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy.

Blood Adv. 2022 Apr 12;6(7):2167-2182. doi: 10.1182/bloodadvances.2021006035.

EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations.

Neuro Oncol. 2022 Feb 1;24(2):313-325. doi: 10.1093/neuonc/noab174.

CAR T cells: Building on the CD19 paradigm.

Eur J Immunol. 2021 Sep;51(9):2151-2163. doi: 10.1002/eji.202049064. Epub 2021 Aug 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验